Tag Archives: Bayer

Roche’s Tecentriq gets a green light to challenge Bayer with first-in-class liver cancer nod

After years of having the previously untreated liver cancer market all to itself, Bayer’s Nexavar is getting its first major competition—and it’s coming from Roche’s Tecentriq. The FDA Friday cleared a combination of the checkpoint inhibitor and fellow Roche med Avastin for previously untreated patients with hepatocellular carcinoma, the most common form of the disease.… Read More »

Bayer version of COVID-19 antimalarial hopeful may come with quality concerns: report

Drugmakers are rushing to supply millions of doses of hydroxychloroquine, a cheap generic in testing as a possible treatment for COVID-19, after public interest sent demand through the roof. But donated batches of the antimalarial drug from Bayer—which haven’t been approved by the FDA—are drawing quality concerns.  The U.S. government has grown worried that millions of doses of… Read More »

With safety data, Bayer could challenge Erleada, Xtandi in prostate cancer: analyst

For years, Johnson & Johnson and the Pfizer-Astellas team have been the only players in their class of prostate-cancer fighters. But Bayer is waiting in the wings, and stellar new safety data could make it a threat. The German drugmaker trumpeted phase 3 data Thursday on its androgen receptor antagonist candidate, darolutamide, showing that the drug… Read More »